DTx soars to $100 million Series B to advance falcon™Platform

We were first introduced to DTx founder and CEO Artie Suckow in June 2017. DTx formed to unlock RNA therapeutics' promise and overcome challenges inherent in delivering this therapeutic class to an array of different tissues and cell types.

​DTx had identified ocular indications as an area of interest to prove their potential revolutionary platform technology, now called FALCON™. This matched up with one pillar of ExSight's investment thesis, the eye's unique "features make it an ideal proving ground for breakthrough technologies." This is particularly so for CNS therapeutics because the retina is part of the brain. Not surprisingly, DTx also had CNS targets in their development plan. 

We stayed in touch with Artie and followed as they executed a development plan remarkably consistent with our investment strategy.

• Compelling science developed and applied to areas of significant clinical need
• An impressive team able to attract other highly qualified individuals
• Clearly defined development plan and inflection points
• Ability to attract non-dilutive impactful funding and value add investment

ExSight joined lead investor Friedman Bioventure Fund, Eli Lilly and Company, and Viva BioInnovator in DTx's Series A. 

The successful Series B raise is a testament to Artie and the entire DTx team's vision and execution. They've been joined by a respected group of new and existing investors to advance clinical development into several therapeutic areas, including ocular, neuromuscular, and CNS diseases. We enthusiastically continued our support into this $100 million Series B. 
If you'd like to join an impressive team of innovators and problem-solvers, DTx is hiring.